PL212238B1 - Nowe związki betamimetyczne, ich zastosowanie, oraz preparat farmaceutyczny zawierający związek - Google Patents

Nowe związki betamimetyczne, ich zastosowanie, oraz preparat farmaceutyczny zawierający związek

Info

Publication number
PL212238B1
PL212238B1 PL375270A PL37527003A PL212238B1 PL 212238 B1 PL212238 B1 PL 212238B1 PL 375270 A PL375270 A PL 375270A PL 37527003 A PL37527003 A PL 37527003A PL 212238 B1 PL212238 B1 PL 212238B1
Authority
PL
Poland
Prior art keywords
alkyl
methyl
compounds
general formula
hydrogen
Prior art date
Application number
PL375270A
Other languages
English (en)
Polish (pl)
Other versions
PL375270A1 (en
Inventor
Thierry Bouyssou
Frank Buettner
Ingo Konetzki
Sabine Pestel
Andreas Schnapp
Hermann Schollenberger
Kurt Schromm
Claudia Heine
Klaus Rudolf
Philipp Lustenberger
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL212238(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PL375270A1 publication Critical patent/PL375270A1/xx
Publication of PL212238B1 publication Critical patent/PL212238B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL375270A 2002-11-15 2003-11-11 Nowe związki betamimetyczne, ich zastosowanie, oraz preparat farmaceutyczny zawierający związek PL212238B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (2)

Publication Number Publication Date
PL375270A1 PL375270A1 (en) 2005-11-28
PL212238B1 true PL212238B1 (pl) 2012-08-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375270A PL212238B1 (pl) 2002-11-15 2003-11-11 Nowe związki betamimetyczne, ich zastosowanie, oraz preparat farmaceutyczny zawierający związek

Country Status (38)

Country Link
EP (2) EP2025338A1 (enFirst)
JP (1) JP4317138B2 (enFirst)
KR (1) KR101092247B1 (enFirst)
CN (3) CN101817800A (enFirst)
AR (2) AR041969A1 (enFirst)
AT (1) ATE430569T1 (enFirst)
AU (1) AU2003285326B2 (enFirst)
BE (1) BE2014C016I2 (enFirst)
BR (1) BRPI0316264B8 (enFirst)
CA (1) CA2506082C (enFirst)
CO (1) CO5570670A2 (enFirst)
CY (2) CY1110500T1 (enFirst)
DE (2) DE10253282A1 (enFirst)
DK (1) DK1562603T3 (enFirst)
EA (1) EA008665B1 (enFirst)
EC (1) ECSP055774A (enFirst)
ES (1) ES2326878T7 (enFirst)
FR (1) FR14C0049I2 (enFirst)
HR (1) HRP20050432B1 (enFirst)
HU (1) HUS1400011I1 (enFirst)
IL (1) IL167900A (enFirst)
LT (1) LTC1562603I2 (enFirst)
LU (1) LU92433I2 (enFirst)
ME (1) ME00354B (enFirst)
MX (1) MXPA05005081A (enFirst)
MY (1) MY136034A (enFirst)
NL (1) NL300650I2 (enFirst)
NO (2) NO334314B1 (enFirst)
NZ (1) NZ540661A (enFirst)
PE (1) PE20040694A1 (enFirst)
PL (1) PL212238B1 (enFirst)
PT (1) PT1562603E (enFirst)
RS (1) RS51607B (enFirst)
SI (1) SI1562603T1 (enFirst)
TW (1) TWI343812B (enFirst)
UA (1) UA81276C2 (enFirst)
WO (1) WO2004045618A2 (enFirst)
ZA (1) ZA200502246B (enFirst)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DK1781298T3 (da) 2004-04-22 2012-05-07 Boehringer Ingelheim Int Lægemiddelkombinationer indeholdende benzoxazin til behandling af luftvejs-sygdomme
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
EP1789394A1 (de) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
PL1917253T3 (pl) * 2005-08-15 2015-06-30 Boehringer Ingelheim Int Sposób wytwarzania betamimetyków
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
NZ567124A (en) 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
KR20080067699A (ko) * 2005-11-09 2008-07-21 베링거 인겔하임 인터내셔날 게엠베하 흡입용 에어로졸 제형
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007093608A1 (de) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
WO2008017638A1 (de) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
NZ579007A (en) * 2007-01-25 2012-02-24 Boehringer Ingelheim Int Method for producing betamimetics
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
EP2444120B1 (en) 2007-12-10 2017-09-27 Novartis AG Spirocyclic amiloride analogues as ENac blockers
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8362064B2 (en) 2008-12-30 2013-01-29 Pulmagen Theraputics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CA2811634C (en) * 2010-09-21 2019-01-15 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110114346B (zh) 2016-12-20 2023-10-31 Inke股份公司 用于制备r-6-羟基-8-[1-羟基-2-[2-(4-甲氧基苯基)-1，1-二甲基乙基氨基乙基]-2h-1，4-苯并噁嗪-3(4h)-酮盐酸盐的改进方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
AR119819A1 (es) 2019-08-28 2022-01-12 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
WO2021252577A1 (en) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
HRP20020845A2 (en) * 2000-04-27 2003-10-31 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Also Published As

Publication number Publication date
ES2326878T3 (es) 2009-10-21
UA81276C2 (en) 2007-12-25
EP2025338A1 (de) 2009-02-18
KR20050075013A (ko) 2005-07-19
EP1562603B3 (de) 2014-01-08
TW200423943A (en) 2004-11-16
EA008665B1 (ru) 2007-06-29
WO2004045618A2 (de) 2004-06-03
ECSP055774A (es) 2005-11-22
CY2014032I2 (el) 2015-12-09
DE50311502D1 (de) 2009-06-18
PE20040694A1 (es) 2004-11-23
NL300650I2 (nl) 2017-11-02
CN1713914A (zh) 2005-12-28
PT1562603E (pt) 2009-06-18
ES2326878T7 (es) 2014-03-11
DE10253282A1 (de) 2004-05-27
TWI343812B (en) 2011-06-21
CA2506082A1 (en) 2004-06-03
FR14C0049I2 (fr) 2015-07-24
SI1562603T1 (sl) 2009-10-31
EP1562603A2 (de) 2005-08-17
DK1562603T3 (da) 2009-09-07
AR087241A2 (es) 2014-03-12
BE2014C016I2 (enFirst) 2023-03-07
HUS1400011I1 (hu) 2022-02-28
AU2003285326B2 (en) 2009-06-04
PL375270A1 (en) 2005-11-28
NO2014005I1 (no) 2014-03-10
BRPI0316264B1 (pt) 2019-04-09
RS20050361A (sr) 2007-04-10
HRP20050432A2 (en) 2006-06-30
NO20052883L (no) 2005-06-14
CN101817800A (zh) 2010-09-01
CA2506082C (en) 2011-06-21
CN101735166A (zh) 2010-06-16
ME00354B (me) 2011-10-10
AR041969A1 (es) 2005-06-01
LTC1562603I2 (lt) 2016-12-12
MEP53608A (en) 2011-05-10
IL167900A (en) 2013-06-27
WO2004045618A3 (de) 2004-09-30
KR101092247B1 (ko) 2011-12-12
NO334314B1 (no) 2014-02-03
ZA200502246B (en) 2006-01-25
BRPI0316264B8 (pt) 2021-05-25
JP4317138B2 (ja) 2009-08-19
CO5570670A2 (es) 2005-10-31
CY1110500T1 (el) 2015-04-29
MXPA05005081A (es) 2005-07-01
BR0316264A (pt) 2005-10-11
MY136034A (en) 2008-07-31
NZ540661A (en) 2007-12-21
AU2003285326A1 (en) 2004-06-15
ATE430569T1 (de) 2009-05-15
RS51607B (sr) 2011-08-31
EP1562603B1 (de) 2009-05-06
FR14C0049I1 (enFirst) 2014-08-08
EA200500715A1 (ru) 2005-12-29
CY2014032I1 (el) 2015-12-09
HRP20050432B1 (en) 2012-01-31
JP2006508140A (ja) 2006-03-09
LU92433I2 (fr) 2014-06-24

Similar Documents

Publication Publication Date Title
PL212238B1 (pl) Nowe związki betamimetyczne, ich zastosowanie, oraz preparat farmaceutyczny zawierający związek
US7056916B2 (en) Medicaments for the treatment of chronic obstructive pulmonary disease
US7135500B2 (en) Dihydroxymethylphenyl derivatives, processes for preparing them, and their use as pharmaceuticals
JP2007537187A (ja) 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
JP4682205B2 (ja) 呼吸器疾患の治療においてβ模倣薬として使用するためのヘテロアリール化合物
CN106995414A (zh) 新的对映异构体纯的β‑激动剂其制备方法及其在药物形式中的用途
JP4785751B2 (ja) 呼吸器疾患の治療のための３−ヒドロキシメチル−４−ヒドロキシ−フェニル誘導体
JP2007537185A (ja) 置換シクロアルキル誘導体、それらの調製方法および薬物としてのそれらの使用
JP2007533684A (ja) 呼吸道疾患を治療するためのベンゾオキサジン
EA013157B1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
US7423036B2 (en) Long-acting betamimetics for the treatment of respiratory complaints
MX2007010363A (es) Nuevos medicamentos para el tratamiento de enfermedades de las vias respiratorias.
HK1144937A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
HK1144938A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
MXPA06010577A (en) Benzoxazine for treating respiratory tract diseases
MXPA06007948A (es) Nuevos beta-2-agonistas de accion prolongada, y su uso como medicamentos